| Document |
Document Title |
|
WO/2021/090855A1 |
The following were discovered: a cyclic peptide compound that interacts with Ras; and an unnatural amino acid that is useful in the production of said cyclic peptide compound. The cyclic peptide compound was also discovered to inhibit bo...
|
|
WO/2021/091967A1 |
The disclosure features macrocyclic compounds, and pharmaceutical compositions and protein complexes thereof, capable of inhibiting Ras proteins, and their uses in the treatment of cancers.
|
|
WO/2021/091982A1 |
The disclosure features macrocyclic compounds, and pharmaceutical compositions and protein complexes thereof, capable of inhibiting Ras proteins, and their uses in the treatment of cancers.
|
|
WO/2021/087268A1 |
Disclosed is a composition and method for a therapeutic treatment that is able to combat certain conditions such as addiction, alcohol dependence, opioid abuse treatment, neurological disorders, neuropathic pain, and combinations thereof...
|
|
WO/2021/082311A1 |
Provided in the present invention are a pea peptide having a supplementary blood glucose reducing function, and a preparation method and a use therefor. The components of the pea peptide at least comprise the peptides pEE, pEK, and pER, ...
|
|
WO/2021/081619A1 |
A skin and/or hair care composition includes a mixture of low-molecular weight hemp (LMWH) peptides, some or all of the peptides are less than about 1 kDa in size. The composition may be a nutraceutical, food product, beverage or topical...
|
|
WO/2021/082310A1 |
A rice peptide having a whitening function, and preparation method and a use therefor. The components of the rice peptide at least comprise the peptides GS, GL, and GF. On the basis of the quality of the rice peptide, the content of the ...
|
|
WO/2021/087084A1 |
Small molecule compounds and corresponding dimers having inhibitory activity against pre-miR-21 RNA and related methods for treatment of neoplastic disease such as cancer and especially cancers expressing miR-21 are disclosed.
|
|
WO/2021/084665A1 |
An agent effective in promoting production of PDGF-BB, and an agent which, using that agent, is effective for activation and anti-aging of the skin through stabilization of mesenchymal stem cells in the skin are provided. The PDGF-BB pro...
|
|
WO/2021/086892A1 |
Disclosed herein are methods of treating Rett syndrome comprising administering trofinetide to a subject in need thereof in which a dosage is provided that may reduce or avoid underexposure, e.g., in low body weight subjects, and/or prov...
|
|
WO/2021/077317A1 |
Provided are an oligopeptide linker intermediate and a preparation method therefor. The method has mild reaction conditions, almost no side reaction, few impurities, and the product is relatively pure and easy to purify.
|
|
WO/2021/079380A1 |
The present invention relates to improved process for the preparation of (2S)-N-{(1S)-1-(2-chlorophenyl)-2-[(3,3-difluorocyclobutyl)-
amino]-2-oxoethyl}-1-(4-cyanopyridin-2-yl)-N-(5-fluoropyridi
n-3-yl)-5-oxopyrrolidine-2-carboxamide and...
|
|
WO/2021/079987A1 |
The present invention relates to a muscle quality improvement agent that contains a γ-glutamyl peptide. This invention makes it possible to provide a muscle quality improvement agent that can prevent a decrease in muscle quality or impr...
|
|
WO/2021/081023A1 |
The present invention provides supramolecular filament and/or sphere compositions and their use as inhalable drug carriers within aerosols. The invention provides insights into peptide designs and supramolecular stability and its crucial...
|
|
WO/2021/075707A1 |
The present invention relates to a method for preparing a silk-derived peptide. A silk-derived peptide preparation method according to the present invention can comprise: a dissolution step of dissolving silk fibroin; a step of treating ...
|
|
WO/2021/077010A1 |
Bifunctional compounds, which find utility as modulators of B-cell lymphoma 6 protein (BCL6; target protein), are described herein. In particular, the bifunctional compounds of the present disclosure contain on one end a Von Hippel-Linda...
|
|
WO/2021/075792A1 |
The present invention relates to a peptide composition, and may particularly be a cosmetic composition and a pharmaceutical composition that exhibit an effect of improving scalp health and preventing, alleviating, or treating hair loss. ...
|
|
WO/2021/076710A1 |
N-Acylated histidine dipeptides of formula are disclosed (I). The compounds are useful for treating breast cancer.
|
|
WO/2021/076902A1 |
Disclosed are small molecule antagonists of human α4β 7 integrin, and methods of using them to treat a number of diseases and conditions.
|
|
WO/2021/074647A1 |
The present invention relates to a method of treating cancer in a subject.
|
|
WO/2021/068080A1 |
Described herein is an immunogenic fusion protein comprising: an immunogenic peptide or an immunogenic variant thereof, the immunogenic peptide comprising the following motifs: - KQPAa; QPAKa; PAKQa; or AKQPa; - NPDPb; PNPDb; DPNPb; or P...
|
|
WO/2021/070920A1 |
A cyclic peptide that has a cyclic structure consisting of 4-30 amino acids or derivative(s) thereof, or a pharmaceutically acceptable salt thereof. In the cyclic structure, the cyclic peptide contains at least carboranylalanine(Cba) and...
|
|
WO/2021/070083A1 |
Compositions for making native-like marine structures are provided. The compositions include materials, typically a limestone and/or ceramic composite, for 3D printing of marine structures. Environmentally-friendly 3D printing and coatin...
|
|
WO/2021/072212A1 |
In some embodiments, the present disclosure provides a compound of Formula (I) as described herein, or a pharmaceutically acceptable salt thereof. In some embodiments, the present disclosure provides a compound of Formula (II) as describ...
|
|
WO/2021/070696A1 |
The present invention provides a cyclic peptide that has, in a ring, an amino acid sequence represented by formula (I): X1-His-Pro-X4-Leu-X6-X7-X8-Ser-X10-His-Phe (where X1, X4, X6, X7, X8, and X10 each independently represent an arbitra...
|
|
WO/2021/064593A1 |
The present invention relates to novel linear ultrashort lipopeptides, pharmaceutical and cosmetic compositions comprising lipopeptides, and lipopeptides for use as drugs in treatment of bacterial infections.
|
|
WO/2021/064361A1 |
The invention relates to the detection of EGYR peptide in a biological sample as a measure of the presence and/or amount of LARP1 protein in the sample. Suitably, the invention relates to methods for quantitative measurement of LARP1 and...
|
|
WO/2021/067460A1 |
The disclosure provides cryptophycin intermediates, cryptophycin analogs, and cryptophycin chimeric molecules useful in treating cancer, as well as methods of producing these compounds and methods of treating cancer.
|
|
WO/2021/064191A1 |
In vitro method for detecting, localising and/or quantifying multidrug resistant (MDR) proteins associated with cells, in a sample containing prokaryotic or eukaryotic cells expressing or capable of expressing MDR proteins. The method co...
|
|
WO/2021/066649A1 |
The invention provides method of treatment comprising administering an AQGV peptide, or a functional analogue thereof, to a human subject, the human subject optionally having impaired kidney function, wherein the treatment of administeri...
|
|
WO/2021/059755A1 |
The present invention addresses the problem of providing a technique that enables sympathetic nerve activation. A composition for sympathetic nerve activation, said composition containing one or more peptides selected from the group cons...
|
|
WO/2021/060441A1 |
To provide a high-molecular-weight degradable multi-arm polyethylene glycol derivative that does not cause cell vacuoles. This degradable polyethylene glycol derivative is represented by formula (1). (In the formula, n1 and n2 are each i...
|
|
WO/2021/059840A1 |
[Problem] To provide: a dipeptide having an inhibitory activity against an angiotensin converting enzyme; and others. [Solution] The purpose can be achieved by an angiotensin converting enzyme (ACE) inhibitor comprising at least one dipe...
|
|
WO/2021/060443A1 |
Provided is a high-molecular-weight branched, degradable polyethylene glycol derivative which does not cause cell vacuoles. The branched, degradable polyethylene glycol derivative represented by formula (1) includes an oligopeptide that ...
|
|
WO/2021/060439A1 |
The present invention addresses the problem of providing: a heterobifunctional monodispersed polyethylene glycol having two adjacent monodispersed polyethylene glycol side chains which can sustainedly release a drug upon the decompositio...
|
|
WO/2021/054927A2 |
The present invention describes compositions containing cholesterol-linker-glutathione conjugates for targeting the brain by overcoming barrier entry to the CNS through the blood brain barrier (BBB), including micelle and liposome forms ...
|
|
WO/2021/047558A1 |
Provided is a flanking sequence pair for SspDnaE, SspDnaB, MxeGyrA, MjaTFIIB, PhoVMA, TvoVMA, Gp41-1, Gp41-8, IMPDH-1, or PhoRadA split intein. The flanking sequence pair comprises: flanking sequence a and flanking sequence b, the flanki...
|
|
WO/2021/047524A1 |
The present invention belongs to the field of medical technology and relates to a class of functional small molecules targeting proteolysis pathways, a preparation and an application thereof. Specifically, the present invention relates t...
|
|
WO/2021/047470A1 |
A method for preparing a peptide amide compound represented by formula (N) and an intermediate thereof; the method has mild reaction conditions, simple operations, high reaction yield, high product purity and convenient post-treatment, a...
|
|
WO/2021/045166A1 |
The present disclosure relates to a composition: that contains a polymer compound; that is capable of promoting cell proliferation; that can be used for wound coverings; and that is for culturing or storing cells and tissues. The composi...
|
|
WO/2020/218727A9 |
The present invention relates to peptides isolated from a protein hydrolysate of Tenebrio molitor mealworm and a composition comprising same as an active ingredient for prevention or treatment of liver injury. According to the present in...
|
|
WO/2021/030743A2 |
The present invention provides a compound of formula (I): A-B-C (I), wherein A is a hydrophobic moiety; B is a peptide, wherein the peptide forms a beta-sheet; and C is a hydrophilic targeting ligand, wherein the hydrophilic targeting li...
|
|
WO/2021/020421A1 |
A cell death inhibitor that has as an effective component thereof ascorbic acid, a derivative thereof, a salt thereof, or a solvate thereof and inhibits cell death induced by transient protein expression in plants. The cell death inhibit...
|
|
WO/2021/020585A1 |
To provide a novel heterocyclic compound which has an effect of inducing the degradation of IRAK-M protein and which is expected to be useful for preventing or treating cancer, fibrosis, infectious diseases, etc., and a medicine comprisi...
|
|
WO/2021/018862A1 |
The present invention relates to SS-31 or composition comprising SS-31 for use in the treatment and/or prevention of aneurysm.
|
|
WO/2021/013086A1 |
A compound as represented by general formula (I) or a stereoisomer, a hydrate, a metabolite, a solvate, a pharmaceutically acceptable salt, or a co-crystal thereof, a composition thereof, a preparation method therefor, and an application...
|
|
WO/2021/014229A1 |
The present invention relates to a compound of formula (I) or an enantiomer, to a pharmaceutically acceptable salt or solvate of this compound, or to a mixture thereof, wherein the core A, the substituents Z, Y and R1i are as defined in ...
|
|
WO/2021/013085A1 |
A compound represented by general formula (I) or stereoisomers thereof, a preparation method therefor, and use thereof in medicine, general formula (I) being shown below, and the definition of each substituent being consistent with that ...
|
|
WO/2021/015041A1 |
A retardant for the progression of aging that comprises a peptide Gly-Pro and/or a peptide Glu-Hyp-Gly, a salt thereof or a chemically modified product of the same.
|
|
WO/2021/013684A1 |
The invention relates to detergents or cleaning agents comprising (i) at least one protease which comprises an amino acid sequence which has at least 70% sequence identity to the amino acid sequence given in SEQ ID No. 1 over its entire ...
|
